Related references
Note: Only part of the references are listed.Effects of Tobacco Smoking on the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma
Janis V. de la Iglesia et al.
CLINICAL CANCER RESEARCH (2020)
A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib
Wayne D. Blosser et al.
Oncotarget (2020)
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen et al.
CANCER DISCOVERY (2019)
Transforming Growth Factor-β Signaling in Immunity and Cancer
Eduard Batlle et al.
IMMUNITY (2019)
Natural Killer Cells as Key Players of Tumor Progression and Angiogenesis: Old and Novel Tools to Divert Their Pro-Tumor Activities into Potent Anti-Tumor Effects
Barbara Bassani et al.
CANCERS (2019)
Neutrophils as a Therapeutic Target in Cancer
Zvi Granot
FRONTIERS IN IMMUNOLOGY (2019)
Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models
Caitlin D. Lowery et al.
CLINICAL CANCER RESEARCH (2019)
Cutting Edge: ICOS-Deficient Regulatory T Cells Display Normal Induction of Il10 but Readily Downregulate Expression of Foxp3
Ashley E. Landuyt et al.
JOURNAL OF IMMUNOLOGY (2019)
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
David S. Hong et al.
CLINICAL CANCER RESEARCH (2018)
Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
Jung-Min Lee et al.
LANCET ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Combining Chk1/2 Inhibition with Cetuximab and Radiation Enhances In Vitro and In Vivo Cytotoxicity in Head and Neck Squamous Cell Carcinoma
Ling Zeng et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Nicholas A. Manieri et al.
TRENDS IN IMMUNOLOGY (2017)
Novel DNA targeted therapies for head and neck cancers: clinical potential and biomarkers
Mary Glorieux et al.
ONCOTARGET (2017)
The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma
Caitlin D. Lowery et al.
CLINICAL CANCER RESEARCH (2017)
Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing
Abhishek D. Garg et al.
CELL DEATH AND DIFFERENTIATION (2017)
Targeting neoantigens to augment antitumour immunity
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
David Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Damage-associated molecular patterns in cancer: a double-edged sword
C. Hernandez et al.
ONCOGENE (2016)
Suppression of Antitumor Immune Responses by Human Papillomavirus through Epigenetic Downregulation of CXCL14
Louis Cicchini et al.
MBIO (2016)
How Do Cytotoxic Lymphocytes Kill Cancer Cells?
Luis Martinez-Lostao et al.
CLINICAL CANCER RESEARCH (2015)
Current Treatment Options for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Assuntina G. Sacco et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Thibault Voron et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms
Constance King et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Glucocorticoid-Induced Tumour Necrosis Factor Receptor-Related Protein: A Key Marker of Functional Regulatory T Cells
Simona Ronchetti et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2015)
The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines
Julian David Guster et al.
RADIOTHERAPY AND ONCOLOGY (2014)
The cellular and molecular origin of tumor-associated macrophages
Ruth A. Franklin et al.
SCIENCE (2014)
Improving the Efficacy of Chemoradiation with Targeted Agents
Meredith A. Morgan et al.
CANCER DISCOVERY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53
Mayur A. Gadhikar et al.
MOLECULAR CANCER THERAPEUTICS (2013)
HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1
Chia-Jung Busch et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Mechanisms of acquired resistance to targeted cancer therapies
Mark R. Lackner et al.
FUTURE ONCOLOGY (2012)
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Bin-Zhi Qian et al.
NATURE (2011)
New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
Yun Dai et al.
CLINICAL CANCER RESEARCH (2010)
Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: N1 versus N2 TAN
Zvi G. Fridlender et al.
CANCER CELL (2009)
The PDZ binding motif of human papillomavirus type 16 E6 induces PTPN13 loss, which allows anchorage-independent growth and synergizes with ras for invasive growth
William C. Spanos et al.
JOURNAL OF VIROLOGY (2008)
The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus
C. C. R. Ragin et al.
JOURNAL OF DENTAL RESEARCH (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1
H Zhao et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
Share Paper
